News Release

Fat cells may inactivate chemotherapeutic drug

Adipocytes metabolize daunorubicin, reducing its ability to kill cancer cells

Peer-Reviewed Publication

American Association for Cancer Research

Bottom Line: Adipocytes, or fat cells, can absorb and metabolize the chemotherapeutic agent daunorubicin, reducing the effectiveness of the drug and potentially contributing to poorer treatment outcomes.

Journal in Which the Study was Published: Molecular Cancer Research, a journal of the American Association for Cancer Research.

Authors: Steven Mittelman, MD, PhD, associate professor of pediatrics and the division chief of pediatric endocrinology at UCLA Mattel Children's Hospital in Los Angeles.

Background: "Anthracyclines such as daunorubicin are important chemotherapy agents used in a variety of cancers in children and adults, including leukemia," Mittelman said. "We need to better understand how some leukemia cells are able to avoid and resist this and other chemotherapies, so we can develop better strategies to improve our treatment outcomes."

Previous research has shown that obesity is associated with poorer outcomes from several kinds of cancer, including breast, colon, ovarian, and prostate cancers. Research has suggested that excess adiposity can affect the "pharmacokinetics" of chemotherapy, or the way drugs are absorbed, metabolized, and excreted from the body.

How the Study Was Conducted and Results: Mittelman and colleagues sought to examine how obesity might alter the effectiveness of daunorubicin. They cocultured human acute lymphoblastic leukemia (ALL) cell lines with adipocytes and treated them with daunorubicin. They also studied whether human adipose tissue from cancer patients could metabolize daunorubicin. They measured the presence of daunorubicin through flow cytometry and liquid chromatography/mass spectrometry, and examined fat cells in bone marrow from children with leukemia.

The study's key findings, according to Mittelman, are:

  • The presence of adipocytes significantly reduced the accumulation of daunorubicin in the ALL cells.

  • The adipocytes absorbed the chemotherapeutic agent, removing it from the leukemia microenvironment. The leukemia cells treated with daunorubicin survived and proliferated better in samples that contained adipocytes.

  • The adipocytes metabolized daunorubicin. Enzymes in the fat cells changed the structure of the chemotherapy molecule, making it much less toxic to the leukemia cells.

Authors' Comments: "The finding that human fat cells can metabolize and inactivate a chemotherapy is novel and surprising," Mittelman said. "This is important for leukemia and a lot of other cancers that grow in the bone marrow or around fat cells, since that means that fat cells might remove chemotherapy from the environment and allow the cancer cells to survive."

Fellow author Etan Orgel, MD, MS, attending physician at Children's Hospital Los Angeles and an assistant professor of clinical pediatrics at the Keck School of Medicine at the University of Southern California, said the study's findings indicate a need for further research to determine whether adipocytes have a similar effect on other types of chemotherapy, and if a similar effect occurs in other types of cancer.

"A deeper understanding of the process could lead clinicians to deliver more effective treatment by choosing or designing chemotherapy drugs that are more resistant to the enzymes in fat cells," he said.

Limitations: Mittelman said the study's primary limitation is that the researchers were unable to measure the exact concentration of daunorubicin in the leukemia cells in patients.

###

Funding and Disclosures: This study was performed at The Saban Research Institute at Children's Hospital Los Angeles, and funded by the National Cancer Institute, the Saban Research Institute, the Office of the Dean of the Keck School of Medicine, a Translational Research Program Award from the Leukemia & Lymphoma Society, the V Foundation for Cancer Research, and the National Center for Advancing Translational Science of the National Institutes of Health. The authors declare no conflicts of interest.

Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 21,900 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policy makers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.